Resources
About Us
Home Report
Store
Asia-Pacific IVD Market
Asia-Pacific IVD Market by Offering (Kits, Software), Technology (Immunoassay, Molecular Diagnostics [PCR, NGS, Microarray], Rapid Tests, Biochemistry), Application (Infectious Diseases, Oncology), Diagnostic Approach - Forecast to 2031
Report ID:MRHC - 1041067 Pages: 230 Jan-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 72 HoursThe Asia-Pacific IVD Market was valued at $21.09 billion in 2023. This market is expected to reach $36.02 billion by 2031, from an estimated $22.44 billion in 2024, at a CAGR of 7% during the forecast period 2024-2031.
In vitro diagnostics (IVD) is focused on analyzing urine, blood, and other bodily fluid samples to provide diagnostic results. IVD tests help diagnose, monitor, screen, and assess susceptibility to diseases. These tests also aid in providing early and targeted treatments, reducing hospital stays, improving health outcomes, and minimizing treatment costs.
The growth of the Asia-Pacific IVD market is attributed to the rising prevalence of chronic and infectious diseases, the growing demand for point-of-care (PoC) and rapid diagnostics, rising awareness regarding early disease diagnosis, rising healthcare expenditures, and increasing funding for research activities. However, stringent technical requirements and regulatory processes for high/moderate-complexity tests and the variance in test results observed in rapid IVD tests restrain the growth of the IVD market. The increasing inclination toward personalized medicine and advancements in genomics and proteomics are expected to create growth opportunities for the players operating in this market. However, the concerns pertaining to false positive results in immunoassays and POC are a major challenge for market growth.
Growing Demand for Point-of-Care (POC) and Rapid Diagnostics is Driving the Growth of this Market
In recent years, there has been a continuous shift toward the decentralization of IVD testing, resulting in the proliferation of point-of-care (PoC) testing services and the development of rapid tests. Point-of-care (PoC) and rapid diagnostics offer benefits such as cost reduction, convenience for patients and clinicians, reduced waiting time for results, and improved testing quality. Traditional laboratory technologies require sophisticated infrastructure, expensive reagents, stable electrical power, long assay times, and skilled and trained staff. In developed countries, hospitals and large clinics have the necessary infrastructure and purchasing power to meet these requirements. However, in the APAC region, the adoption of PoC can be proven useful for the testing in resource-limited testing.
Additionally, key companies are developing various tests and instruments for rapid disease diagnosis. Some of the product’s approval and launch in recent years are as follows:
- In February 2022, Mylab Discovery Solutions Pvt Ltd (India) launched CoviSwift, the Point of Care (POC) testing solution.
- In May 2020, the Japanese government approved the Rapid Antigen Kit to Detect COVID-19 manufactured by Fujirebio (Japan)
Click here to: Get Free Sample Pages of this Report
Rising Prevalence of Chronic Diseases is Driving the Growth of this Market
Chronic diseases are often associated with the elderly population due to the declining bodily functions and immunity among this population segment. Aging is associated with progressive deterioration in the structure and functioning of organs. The elderly population is more prone to various chronic diseases. According to the World Bank, the share of the elderly population (aged 65 and above) in Japan is among the highest in the world and is growing at a CAGR of 1.1% (from 2016 to 2021). In 2021, the share of the elderly population in Japan was estimated at 29.8% of the country’s total population (source: World Bank).
The prevalence of chronic diseases and conditions such as cancer, diabetes, arthritis, and heart disease is on the rise in Asia-Pacific countries. In 2021, 140.9 million people were living with diabetes in China, which is expected to reach 174.4 million by 2045 (Source: IDF). Similarly, in 2021, 74.2 million people were living with diabetes in India, which is expected to reach 124.9 million by 2045 (Source: IDF). As IVD tests are widely adopted for glucose monitoring, the prevalence of diabetes drives the adoption of IVD devices.
The growth in the geriatric population and social behaviours such as tobacco and alcohol consumption, physical inactivity, and unhealthy diets are major factors driving a steady increase in the number of people suffering from chronic diseases. The growth in the elderly population and the associated increase in the burden of chronic disease is increasing the demand for IVD testing in Asia-Pacific.
Key Findings of the Market Study:
In 2024, the Kits & Reagents Segment is Expected to Dominate this Market
Based on offering, the Asia-Pacific IVD market is segmented into reagents and kits, instruments, and software & services. In 2024, the kits & reagents segment is expected to account for the largest share of the market. The continuous advancements in the development of reagents and kits, high adoption and recurring consumption of IVD kits, and wide availability of consumables support the largest share of the market. The increasing trend of self-testing and adoption of POC diagnostic testing is contributing to the largest share of this segment.
In 2024, the Molecular Diagnostics Segment is Expected to Account for the Largest Share of the Market
Based on technology, the Asia-Pacific IVD market is segmented into immunoassay/immunochemistry, biochemistry/clinical chemistry, molecular diagnostics, point-of-care (POC) diagnostics, whole blood glucose monitoring, microbiology, hematology, coagulation/hemostasis, urinalysis, and other technologies. In 2024, the molecular diagnostics segment was expected to account for the largest share of the market. The growing prevalence of infectious diseases is also increasing the demand for molecular diagnostics. For instance, In Australia, between 2020 to 2021, there were more than 324,000 hospitalizations for infectious diseases. The most common causes of infectious disease hospitalization were lower respiratory tract infections, including pneumonia and bronchitis. (Source: Australian Institute of Health and Welfare). Additionally, technological innovations and the advantages of molecular diagnostics tests, such as cost-effectiveness, rapid results, and high sensitivity and specificity over laboratory tests.
The Cardiology Segment Is Projected to Register the Highest CAGR During the Forecast Period
Based on application, the Asia-Pacific in vitro diagnostics (IVD) market is segmented into infectious diseases, oncology, diabetes, cardiology, nephrology, autoimmune disorders, and other applications. The cardiology segment is expected to register the highest CAGR during the forecast period. Cardiovascular diseases (CVD) remain the leading cause of death globally. IVD testing is used for biomarker detection in cardiology. The early-stage biomarkers of CVD can potentially save many lives and help alleviate the global burden of CVD. According to the American Heart Association, in 2020 highest mortality rates due to cardiovascular diseases were reported in Central Asia and Eastern Asia-Pacific. Thus, the high prevalence of cardiovascular diseases is expected to drive the demand for IVD testing in Asia-Pacific.
In 2024, the Laboratory Testing Segment is Expected to Dominate this Market
Based on diagnostic approach, the Asia-Pacific IVD market is segmented into laboratory testing, OTC/self-testing, and point-of-care testing. In 2024, the laboratory testing segment is expected to account for the largest share of the market. The large market share of this segment is primarily attributed to its higher accuracy and reliability, lower costs, and availability of several IVD tests in laboratory settings. The laboratories usually include a quality assurance program and address pre- and post-analytical concerns, improving and maintaining the accuracy of laboratory testing.
The Hospitals & Clinics Segment Is Projected to Register the Highest CAGR During the Forecast Period
Based on end user, the Asia-Pacific in vitro diagnostics (IVD) market is segmented into diagnostic laboratories, hospitals & clinics, home healthcare, and other end users, which include nursing homes, academic & research institutes, ambulatory care centers, and transfusion laboratories. The hospitals & clinics segment is expected to register the highest CAGR during the forecast period. The highest CAGR of this segment is attributed to the increasing number of hospitalizations due to various diseases requiring diagnosis and the rise in the number of hospitals and clinics in the region, leading to growth in the utilization of diagnostic products.
China: Fastest Growing Market
China is expected to register the highest CAGR during the forecast period. The highest CAGR of this regional market is attributed to the rising prevalence of infectious & chronic diseases, the growing aging population, and the increasing adoption of self-testing. Additionally, China is one of the world's most populous countries, with a population of over 1.41 billion in 2021 (Source: World Bank). There is an increasing burden on the country's healthcare system due to the growing elderly population, high prevalence of cancer, and increasing sedentary lifestyle. According to the International Diabetes Federation (IDF), China has the highest number of people with diabetes globally. In 2021, 140.9 million people were living with diabetes in China, which is expected to reach 174.4 million by 2045 (Source: IDF). With the increasing number of chronic conditions, the demand for IVD testing is increasing in the country.
Asia-Pacific IVD Market: Key Players
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years. The key players operating in the Asia-Pacific IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Sysmex Corporation (Japan), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Seegene Inc. (South Korea), Illumina, Inc. (U.S.), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), QuidelOrtho Corporation (U.S.), and Agilent Technologies Inc. (U.S.).
Report Summary:
|
Particular |
Details |
|
Number of Pages |
~230 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
7% |
|
Estimated Market Size (Value) |
$36.02 billion by 2031 |
|
Segments Covered |
by Offering
by Technology
by Application
by Diagnostic Approach
by End User
by Country/Region
|
|
Countries Covered |
Asia-Pacific (China, Japan, India, Australia, South Korea, Thailand, Singapore, Indonesia, RoAPAC) |
|
Key Companies |
Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Sysmex Corporation (Japan), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Seegene Inc. (South Korea), Illumina, Inc. (U.S.), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), QuidelOrtho Corporation (U.S.), and Agilent Technologies Inc. (U.S.). |
Key questions answered in the report:
The Asia-Pacific IVD market is segmented based on product & solution (reagents & kits, systems, and software & services) and a wide range of technologies (immunoassay/immunochemistry, biochemistry/clinical chemistry, molecular diagnostics, microbiology, hematology, coagulation/hemostasis, urinalysis, and other technologies) offered by key companies to various end users, such as diagnostic laboratories, hospitals & clinics, home healthcare, and other end users. The Asia-Pacific IVD market studied in this report involves the value analysis of various segments and sub-segments of in-vitro diagnostics at regional and country levels.
The Asia-Pacific IVD market is projected to reach $36.02 billion by 2031, at a CAGR of 7.0% during the forecast period.
The kits & reagents segment is estimated to account for the largest share of the Asia-Pacific IVD market in 2024. Factors such as the high burden of diseases, the high adoption of rapid diagnostic test kits, and the presence of initiatives supporting early disease diagnosis are responsible for the largest market share.
Based on the technology, the molecular diagnostics segment is projected to create more traction owing to the technological innovations and the advantages of rapid immunoassay tests, such as cost-effectiveness, rapid results, and high sensitivity & specificity over laboratory tests.
Based on application, the cardiology segment is projected to create more traction during the forecast period due to the growing burden of cardiovascular diseases and rising demand for early diagnosis.
Based on end user, the hospitals & clinics segment is projected to create more traction during the forecast period due to a large number of hospitalizations due to various diseases, the rising geriatric population, increasing healthcare access & expenditure, and the rising prevalence of healthcare-associated infections (HAIs).
The growth of the Asia-Pacific IVD market is attributed to the rising prevalence of chronic and infectious diseases, the growing demand for point-of-care (PoC) and rapid diagnostics, rising awareness regarding early disease diagnosis, rising healthcare expenditures, and increasing funding for research activities. The increasing inclination toward personalized medicine and advancements in genomics and proteomics are expected to create growth opportunities for the players operating in this market.
The key players operating in the Asia-Pacific IVD market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Sysmex Corporation (Japan), bioMérieux SA (France), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Seegene Inc. (South Korea), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Shenzhen Mindray Bio-Medical Electronics Co., Ltd (China), Siemens Healthineers AG (Germany), Thermo Fisher Scientific Inc. (U.S.), QuidelOrtho Corporation (U.S.), and Agilent Technologies Inc. (U.S.).
China is expected to offer significant growth opportunities owing to the government initiatives to improve the healthcare infrastructure in the country, the rising prevalence of infectious diseases, and the growth in the geriatric population.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency & Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for this Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Increasing Prevalence of Chronic and Infectious Diseases
4.2.2. Growing Demand for Point-of-Care and Rapid Diagnostics
4.2.3. Rising Awareness Regarding Early Disease Diagnosis
4.2.4. Rising Healthcare Expenditure
4.2.5. Increasing Funding for Research Activities
4.3. Restraints
4.3.1. Stringent Technical Requirements and Regulatory Processes for High/Moderate Complexity Tests
4.3.2. Variance in Test Results Observed in Rapid IVD Tests
4.4. Opportunities
4.4.1. Increasing Inclination Towards Personalized Medicine
4.4.2. Advancements in Genomics and Proteomics
4.5. Challenges
4.5.1. Concerns Pertaining to False Positive Results in Immunoassays and POC
4.6. Trends
4.7. Pricing Analysis
4.8. Regulatory Analysis
4.9. Porters Five Force Analysis
4.9.1. Bargaining Power of Buyers
4.9.2. Bargaining Power of Suppliers
4.9.3. Threat of Substitute
4.9.4. Threat of New Entrant
4.9.5. Degree of Competition
5. Asia-Pacific In Vitro Diagnostics Market Assessment—by Offering
5.1. Overview
5.2. Reagents & Kits
5.3. Instruments
5.4. Software & Services
6. Asia-Pacific In Vitro Diagnostics Market Assessment—by Technology
6.1. Overview
6.2. Molecular Diagnostics
6.2.1. Polymerase Chain Reaction (PCR)
6.2.2. Hybridization
6.2.3. Isothermal Nucleic Acid Amplification Technology
6.2.4. DNA Sequencing & Next-generation Sequencing
6.2.5. Microarrays
6.2.6. Mass Spectrometry
6.2.7. Other Molecular Diagnostic Technologies
6.3. Point of Care Diagnostics
6.3.1. Lateral Flow Assays/Rapid Tests
6.3.2. PoC Molecular Diagnostics
6.3.3. Other POC
6.4. Immunoassay/Immunochemistry
6.4.1. Enzyme-linked Immunosorbent Assays (ELISA)
6.4.2. Enzyme-linked Immunospot Assays (ELISPOT)
6.4.3. Western Blotting
6.4.4. Radioimmunoassay
6.5. Biochemistry/Clinical Chemistry
6.5.1. Metabolic Panels
6.5.2. Electrolyte Panels
6.5.3. Liver Panels
6.5.4. Lipid Profiles
6.5.5. Renal Profiles
6.5.6. Thyroid Function Panels
6.6. Whole Blood Glucose Monitoring
6.7. Hematology
6.8. Microbiology
6.9. Coagulation & Hemostasis
6.10. Urinalysis
6.11. Other IVD Technologies
7. Asia-Pacific In Vitro Diagnostics Market Assessment—by Application
7.1. Overview
7.2. Infectious Diseases
7.2.1. COVID-19 Testing
7.2.2. Sexually Transmitted Diseases Testing
7.2.3. Healthcare-associated Infections
7.2.4. Hepatitis
7.2.5. HIV
7.2.6. Tropical Diseases
7.2.7. Influenza
7.2.8. Respiratory Infections (Excluding Influenza)
7.2.9. Other Infectious Diseases
7.3. Oncology
7.4. Cardiology
7.5. Diabetes
7.6. Autoimmune Disorders
7.7. Nephrology
7.8. Other Applications
8. Asia-Pacific In Vitro Diagnostics Market Assessment—by Diagnostic Approach
8.1. Overview
8.2. Lab Testing
8.3. OTC/Self-testing
8.4. Point-of-care Testing
9. Asia-Pacific In Vitro Diagnostics Market Assessment—by End User
9.1. Overview
9.2. Hospitals & Clinics
9.3. Diagnostic Laboratories
9.4. Home Healthcare
9.5. Other End Users
10. Asia-Pacific In Vitro Diagnostics Market Assessment—by Country/Region
10.1. Overview
10.2. China
10.3. Japan
10.4. India
10.5. Australia
10.6. South Korea
10.7. Thailand
10.8. Singapore
10.9. Indonesia
10.10. Rest of Asia-Pacific
11. Competition Analysis
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Market Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
11.5. Market Share Analysis/Market Ranking (2022)
12. Company Profiles (Company Overview, Financial Overview, Product Portfolio, Strategic Developments, SWOT Analysis)
12.1. Abbott Laboratories
12.2. Becton, Dickinson and Company
12.3. Sysmex Corporation
12.4. bioMérieux SA
12.5. Bio-Rad Laboratories, Inc.
12.6. Danaher Corporation
12.7. F. Hoffmann-La Roche Ltd.
12.8. Seegene Inc.
12.9. Illumina, Inc.
12.10. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
12.11. Siemens Healthineers AG
12.12. Thermo Fisher Scientific Inc.
12.13. QuidelOrtho Corporation
12.14. Agilent Technologies Inc.
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided.)
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Asia-Pacific In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 2 Asia-Pacific In Vitro Diagnostics Reagents & Kits Market, by Country/Region, 2022–2031 (USD Million)
Table 3 Asia-Pacific In Vitro Diagnostics Instruments Market, by Country/Region, 2022–2031 (USD Million)
Table 4 Asia-Pacific In Vitro Diagnostics Software & Services Market, by Country/Region, 2022–2031 (USD Million)
Table 5 Asia-Pacific In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 6 Asia-Pacific Molecular Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 7 Asia-Pacific Molecular Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 8 Asia-Pacific Polymerase Chain Reaction Market, by Country/Region, 2022–2031 (USD Million)
Table 9 Asia-Pacific Hybridization Market, by Country/Region, 2022–2031 (USD Million)
Table 10 Asia-Pacific Isothermal Nucleic Acid Amplification Technology Market, by Country/Region, 2022–2031 (USD Million)
Table 11 Asia-Pacific DNA Sequencing & Next-Generation Sequencing Market, by Country/Region, 2022–2031 (USD Million)
Table 12 Asia-Pacific Microarrays Market, by Country/Region, 2022–2031 (USD Million)
Table 13 Asia-Pacific Mass Spectrometry Market, by Country/Region, 2022–2031 (USD Million)
Table 14 Asia-Pacific Other Molecular Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 15 Asia-Pacific Point-of-care Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 16 Asia-Pacific Point-of-care Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 17 Asia-Pacific Point-of-care Diagnostics Market for Lateral Flow Assays/Rapid Tests, by Country/Region, 2022–2031 (USD Million)
Table 18 Asia-Pacific Molecular POC Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 19 Asia-Pacific Other Point-of-care Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 20 Asia-Pacific Immunoassay/Immunochemistry Market, by Type, 2022–2031 (USD Million)
Table 21 Asia-Pacific Immunoassay/Immunochemistry Market, by Country/Region, 2022–2031 (USD Million)
Table 22 Asia-Pacific Enzyme-linked Immunosorbent Assays (ELISA) Market, by Country/Region, 2022–2031 (USD Million)
Table 23 Asia-Pacific Enzyme-linked Immunospot Assays (ELISPOT) Market, by Country/Region, 2022–2031 (USD Million)
Table 24 Asia-Pacific Western Blotting Market, by Country/Region, 2022–2031 (USD Million)
Table 25 Asia-Pacific Radioimmunoassay Market, by Country/Region, 2022–2031 (USD Million)
Table 26 Asia-Pacific Biochemistry/Clinical Chemistry Market, by Type, 2022–2031 (USD Million)
Table 27 Asia-Pacific Biochemistry/Clinical Chemistry Market, by Country/Region, 2022–2031 (USD Million)
Table 28 Asia-Pacific Metabolic Panels Market, by Country/Region, 2022–2031 (USD Million)
Table 29 Asia-Pacific Electrolyte Panels Market, by Country/Region, 2022–2031 (USD Million)
Table 30 Asia-Pacific Liver Panels Market, by Country/Region, 2022–2031 (USD Million)
Table 31 Asia-Pacific Lipid Profiles Market, by Country/Region, 2022–2031 (USD Million)
Table 32 Asia-Pacific Renal Profiles Market, by Country/Region, 2022–2031 (USD Million)
Table 33 Asia-Pacific Thyroid Functional Panels Market, by Country/Region, 2022–2031 (USD Million)
Table 34 Asia-Pacific Whole Blood Glucose Monitoring Market, by Country/Region, 2022–2031 (USD Million)
Table 35 Asia-Pacific Microbiology Market, by Country/Region, 2022–2031 (USD Million)
Table 36 Asia-Pacific Hematology Market, by Country/Region, 2022–2031 (USD Million)
Table 37 Asia-Pacific Coagulation and Hemostasis Market, by Country/Region, 2022–2031 (USD Million)
Table 38 Asia-Pacific Urinalysis Market, by Country/Region, 2022–2031 (USD Million)
Table 39 Asia-Pacific Other IVD Technologies Market, by Country/Region, 2022–2031 (USD Million)
Table 40 Asia-Pacific In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 41 Asia-Pacific In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 42 Asia-Pacific In Vitro Diagnostics Market for Infectious Diseases, by Country/Region, 2022–2031 (USD Million)
Table 43 Asia-Pacific In Vitro Diagnostics Market for COVID-19 Testing, by Country/Region, 2022–2031 (USD Million)
Table 44 Asia-Pacific In Vitro Diagnostics Market for Sexually Transmitted Diseases Testing, by Country/Region, 2022–2031 (USD Million)
Table 45 Asia-Pacific In Vitro Diagnostics Market for Healthcare-associated Infections, by Country/Region, 2022–2031 (USD Million)
Table 46 Asia-Pacific In Vitro Diagnostics Market for Hepatitis, by Country/Region, 2022–2031 (USD Million)
Table 47 Asia-Pacific In Vitro Diagnostics Market for Tropical Diseases, by Country/Region, 2022–2031 (USD Million)
Table 48 Asia-Pacific In Vitro Diagnostics Market for Influenza, by Country/Region, 2022–2031 (USD Million)
Table 49 Asia-Pacific In Vitro Diagnostics Market for Respiratory Infections (Excluding Influenza), by Country/Region 2022–2031 (USD Million)
Table 50 Asia-Pacific In Vitro Diagnostics Market for Other Infectious Diseases, by Country/Region, 2022–2031 (USD Million)
Table 51 Asia-Pacific In Vitro Diagnostics Market for Oncology, by Country/Region, 2022–2031 (USD Million)
Table 52 Asia-Pacific In Vitro Diagnostics Market for Diabetes, by Country/Region, 2022–2031 (USD Million)
Table 53 Asia-Pacific In Vitro Diagnostics Market for Cardiology, by Country/Region, 2022–2031 (USD Million)
Table 54 Asia-Pacific In Vitro Diagnostics Market for Nephrology, by Country/Region, 2022–2031 (USD Million)
Table 55 Asia-Pacific In Vitro Diagnostics Market for Autoimmune Disorders, by Country/Region, 2022–2031 (USD Million)
Table 56 Asia-Pacific In Vitro Diagnostics Market for Other Applications, by Country/Region, 2022–2031 (USD Million)
Table 57 Asia-Pacific In Vitro Diagnostics Market, by Diagnostic Approach, 2022–2031 (USD Million)
Table 58 Asia-Pacific In Vitro Diagnostics Market for Laboratory Testing, by Country/Region, 2022–2031 (USD Million)
Table 59 Asia-Pacific In Vitro Diagnostics Market for OTC/Self-testing, by Country/Region, 2022–2031 (USD Million)
Table 60 Asia-Pacific In Vitro Diagnostics Market for Point-of-care Testing, by Country/Region, 2022–2031 (USD Million)
Table 61 Asia-Pacific In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 62 Asia-Pacific In Vitro Diagnostics Market for Hospitals & Clinics, by Country/Region, 2022–2031 (USD Million)
Table 63 Asia-Pacific In Vitro Diagnostics Market for Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 64 Asia-Pacific In Vitro Diagnostics Market for Home Healthcare, by Country/Region, 2022–2031 (USD Million)
Table 65 Asia-Pacific In Vitro Diagnostics Market for Other End Users, by Country/Region, 2022–2031 (USD Million)
Table 66 China In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 67 China In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 68 China In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
Table 69 China In Vitro Diagnostics Market for Point-of-Care Diagnostics, by Type, 2022–2031 (USD Million)
Table 70 China In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
Table 71 China In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
Table 72 China In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 73 China In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 74 China In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
Table 75 China In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 76 Japan In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 77 Japan In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 78 Japan In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
Table 79 Japan In Vitro Diagnostics Market for Point-of-Care Diagnostics, by Type, 2022–2031 (USD Million)
Table 80 Japan In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
Table 81 Japan In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
Table 82 Japan In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 83 Japan In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 84 Japan In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
Table 85 Japan In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 86 India In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 87 India In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 88 India In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
Table 89 India In Vitro Diagnostics Market for Point-of-Care Diagnostics, by Type, 2022–2031 (USD Million)
Table 90 India In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
Table 91 India In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
Table 92 India In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 93 India In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 94 India In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
Table 95 India In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 96 Australia In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 97 Australia In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 98 Australia In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
Table 99 Australia In Vitro Diagnostics Market for Point-of-Care Diagnostics, by Type, 2022–2031 (USD Million)
Table 100 Australia In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
Table 101 Australia In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
Table 102 Australia In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 103 Australia In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 104 Australia In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
Table 105 Australia In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 106 South Korea In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 107 South Korea In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 108 South Korea In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
Table 109 South Korea In Vitro Diagnostics Market for Point-of-Care Diagnostics, by Type, 2022–2031 (USD Million)
Table 110 South Korea In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
Table 111 South Korea In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
Table 112 South Korea In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 113 South Korea In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 114 South Korea In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
Table 115 South Korea In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 116 Thailand In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 117 Thailand In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 118 Thailand In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
Table 119 Thailand In Vitro Diagnostics Market for Point-of-Care Diagnostics, by Type, 2022–2031 (USD Million)
Table 120 Thailand In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
Table 121 Thailand In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
Table 122 Thailand In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 123 Thailand In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 124 Thailand In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
Table 125 Thailand In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 126 Singapore In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 127 Singapore In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 128 Singapore In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
Table 129 Singapore In Vitro Diagnostics Market for Point-of-Care Diagnostics, by Type, 2022–2031 (USD Million)
Table 130 Singapore In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
Table 131 Singapore In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
Table 132 Singapore In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 133 Singapore In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 134 Singapore In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
Table 135 Singapore In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 136 Indonesia In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 137 Indonesia In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 138 Indonesia In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
Table 139 Indonesia In Vitro Diagnostics Market for Point-of-Care Diagnostics, by Type, 2022–2031 (USD Million)
Table 140 Indonesia In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
Table 141 Indonesia In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
Table 142 Indonesia In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 143 Indonesia In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 144 Indonesia In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
Table 145 Indonesia In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 146 Rest of Asia-Pacific In Vitro Diagnostics Market, by Offering, 2022–2031 (USD Million)
Table 147 Rest of Asia-Pacific In Vitro Diagnostics Market, by Technology, 2022–2031 (USD Million)
Table 148 Rest of Asia-Pacific In Vitro Diagnostics Market for Molecular Diagnostics, by Type, 2022–2031 (USD Million)
Table 149 Rest of Asia-Pacific In Vitro Diagnostics Market for Point-of-Care Diagnostics, by Type, 2022–2031 (USD Million)
Table 150 Rest of Asia-Pacific In Vitro Diagnostics Market for Immunoassay/Immunochemistry, by Type, 2022–2031 (USD Million)
Table 151 Rest of Asia-Pacific In Vitro Diagnostics Market for Biochemistry/Clinical Chemistry, by Type, 2022–2031 (USD Million)
Table 152 Rest of Asia-Pacific In Vitro Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 153 Rest of Asia-Pacific In Vitro Diagnostics Market for Infectious Diseases, by Type, 2022–2031 (USD Million)
Table 154 Rest of Asia-Pacific In Vitro Diagnostics Market, by Diagnostics Approach, 2022–2031 (USD Million)
Table 155 Rest of Asia-Pacific In Vitro Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 156 Recent Developments, by Company (2020-2023)
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Size Estimation
Figure 7 Asia-Pacific In Vitro Diagnostics Market, by Offering, 2024 VS. 2031 (USD Million)
Figure 8 Asia-Pacific In Vitro Diagnostics Market, by Technology, 2024 VS. 2031 (USD Million)
Figure 9 Asia-Pacific In Vitro Diagnostics Market, by Application, 2024 VS. 2031 (USD Million)
Figure 10 Asia-Pacific In Vitro Diagnostics Market, by Diagnostic Approach, 2024 VS. 2031 (USD Million)
Figure 11 Asia-Pacific In Vitro Diagnostics Market, by End User, 2024 VS. 2031 (USD Million)
Figure 12 Asia-Pacific In Vitro Diagnostics Market, by Country
Figure 13 Factors Affecting Market Growth
Figure 14 Asia-Pacific In Vitro Diagnostics Market, by Offering, 2024 VS. 2031 (USD Million)
Figure 15 Asia-Pacific In Vitro Diagnostics Market, by Technology, 2024 VS. 2031 (USD Million)
Figure 16 Asia-Pacific In Vitro Diagnostics Market, by Application, 2024 VS. 2031 (USD Million)
Figure 17 Asia-Pacific In Vitro Diagnostics Market, by Diagnostic Approach, 2024 VS. 2031 (USD Million)
Figure 18 Asia-Pacific In Vitro Diagnostics Market, by End User, 2024 VS. 2031 (USD Million)
Figure 19 Asia-Pacific In Vitro Diagnostics Market, by Country, 2024 VS. 2031 (USD Million)
Figure 20 Asia-Pacific: In Vitro Diagnostics Market Snapshot
Figure 21 Key Growth Strategies Adopted by Leading Players, 2020—2023
Figure 22 Asia-Pacific In Vitro Diagnostics Market: Competitive Benchmarking, by Offering
Figure 23 Asia-Pacific In Vitro Diagnostics Market: Competitive Dashboard
Figure 24 Asia-Pacific In Vitro Diagnostics Market: Market Share Analysis (2022)
Figure 25 Abbott Laboratories: Financial Snapshot (2022)
Figure 26 Becton, Dickinson and Company: Financial Snapshot (2022)
Figure 27 Sysmex Corporation: Financial Snapshot (2022)
Figure 28 bioMérieux SA: Financial Snapshot (2022)
Figure 29 Bio-Rad Laboratories, Inc.: Financial Snapshot (2022)
Figure 30 Danaher Corporation: Financial Snapshot (2022)
Figure 31 F. Hoffmann-La Roche Ltd.: Financial Snapshot (2022)
Figure 32 Illumina, Inc.: Financial Snapshot (2022)
Figure 33 Shenzhen Mindray Bio-Medical Electronics Co., Ltd: Financial Snapshot (2022)
Figure 34 Siemens Healthineers AG: Financial Snapshot (2022)
Figure 35 Thermo Fisher Scientific Inc.: Financial Snapshot (2022)
Figure 36 QuidelOrtho Corporation: Financial Snapshot (2022)
Figure 37 Agilent Technologies Inc.: Financial Snapshot (2022)
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Asia-Pacific Healthcare IT Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Asia-Pacific Telehealth Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Asia-Pacific Molecular Diagnostics Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
Asia-Pacific Livestock Diagnostics Market - Opportunity Analysis and Industry Forecast (2024-2030)
Published Date: Jul-2024
South East Asia IVD Market - Opportunity Analysis And Industry Forecast (2024-2030)
Published Date: Jul-2024
